Skip to content
Open Imaging Index
MRI Breast

ISPY2

I-SPY 2 Breast Dynamic Contrast Enhanced MRI Trial (ISPY2)

Breast MRI repeated during neoadjuvant treatment of locally advanced breast cancer, from an adaptive drug trial that uses tumor volume change on MRI to steer randomization. 719 women with enhancement maps, tumor volume masks and pathologic response.

Go to dataset Edit Report

Overview

ISPY2 is the TCIA image collection of the I-SPY 2 TRIAL (NCT01042379), a multi-center adaptive trial that tests new drugs for high-risk, locally advanced breast cancer given before surgery as neoadjuvant chemotherapy. The trial uses the change in tumor volume on dynamic contrast-enhanced (DCE) MRI during treatment to steer randomization. The collection covers patients randomized between 2010 and 2016 and was released in May 2022 under CC BY 4.0.

Composition

The collection holds 719 women aged 24 to 73 (mean 48.9 years) with 2,688 MRI studies, 32,411 DICOM series and about 5.6 million images. Each patient had up to four exams: before treatment (T0), after three weeks of paclitaxel-based therapy (T1), between the paclitaxel and anthracycline regimens (T2) and before surgery (T3). Counted from the open metadata digest, 717 patients have a T0 study, 690 a T1, 647 a T2 and 634 a T3.

These 719 patients are one part of "I-SPY2 Imaging Cohort 1". The other 266 patients of that cohort are published as the separate TCIA collection ACRIN-6698 (ACRIN 6698/I-SPY2 Breast DWI). The collection page provides a combined manifest for all 985 patients and warns that results from the 719 alone are not comparable to published trial results. A clinical spreadsheet for the 985 patients carries pathologic outcome and receptor status, and a separate sheet gives four MRI features for a 384-patient subset.

Acquisition

More than 22 sites scanned patients prone on 1.5 T or 3 T systems with a dedicated breast coil, following a shared protocol. Each patient stayed on the same scanner configuration for all visits. The collection includes axial bilateral T2-weighted series and T1-weighted DCE series. DWI was acquired but is not included. Per the metadata digest, most patients were scanned on GE systems, followed by Siemens and Philips.

Annotations

Each DCE study comes with derived objects from the trial's analysis: an ipsilateral cropped DCE series, early and late percent enhancement maps, a signal enhancement ratio (SER) map, and a functional tumor volume (FTV) analysis mask stored as DICOM SEG. The mask encodes thresholds and manually drawn volume-of-interest and exclusion regions.

Known limitations

  • The T2-weighted series are not curated.
  • Some derived objects are not strictly DICOM compliant.
  • FTV values stored in the derived objects can differ slightly from the values used in the trial analysis.
  • DWI is missing from this collection.

Cohort

Aggregate numbers from the sources below. Bars are relative to the 719 subjects.

Sex

  • Female 719 100%

Demographic Summary of Available Imaging in TCIA ISPY2 collection page (version 1, updated 2022/05/02)

Anatomy

  • Breast 719 100%

Summary table in TCIA ISPY2 collection page (version 1, updated 2022/05/02)

Age

mean 48.9 ± 11, median 49, range 24 to 73

No age bins reported.

Demographic Summary of Available Imaging in TCIA ISPY2 collection page (version 1, updated 2022/05/02)

Condition

Groups can overlap

  • Breast cancer 719 100%

Summary table in TCIA ISPY2 collection page (version 1, updated 2022/05/02)

Scanner vendor

  • GE HealthCare 426 59%
  • Siemens Healthineers 210 29%
  • Philips 83 12%

Patient ID, Manufacturer columns in TCIA ISPY2 metadata digest for the 719-patient manifest (ISPY2-719-patients-only-manifest-Jan-2022-nbia-digest.xlsx, open download), counted per unique Patient ID

License and access

Our reading of the license, not legal advice. Before you use the data, read the original license and confirm that your use is allowed. We take no responsibility for how you use a dataset. Full disclaimer

Access
Open download

Download without an account

DICOM images are downloaded with the TCIA Data Retriever from a manifest file. No account is needed. A second manifest on the same page downloads the full I-SPY2 Imaging Cohort 1 (985 patients), which adds the 266 patients of the separate ACRIN-6698 collection. The clinical spreadsheet for all 985 patients is an open XLSX download.

Access page

Creative Commons Attribution 4.0 International

Use, share and adapt the data for any purpose, including commercial use, as long as you credit the creators.

Original license text Version read: 4.0 Checked 2026-10-07

What you can do

  • Yes
  • Yes
  • Yes
  • Yes
  • Yes

What you can share

  • Yes
  • Yes
  • Yes

What you must do

  • Yes
  • Share alike No
  • No
  • No
  • Manuscript review No
  • Release code No
  • Return results No
  • Delete after use No

Limits

  • No
  • Location limits No

Citation

Li, W., Newitt, D. C., Gibbs, J., Wilmes, L. J., Jones, E. F., Arasu, V. A., Strand, F., Onishi, N., Nguyen, A. A.-T., Kornak, J., Joe, B. N., Price, E. R., Ojeda-Fournier, H., Eghtedari, M., Zamora, K. W., Woodard, S. A., Umphrey, H., Bernreuter, W., Nelson, M., ... Hylton, N. M. (2022). I-SPY 2 Breast Dynamic Contrast Enhanced MRI Trial (ISPY2) (Version 1) [Data set]. The Cancer Imaging Archive. https://doi.org/10.7937/TCIA.D8Z0-9T85

Sources

Every number on this page comes from one of these documents. Each chart names the table or page it is taken from. The raw numbers are in stats.csv.